تحميل...
Failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer
We report the failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer. A 76-year-old man was admitted to our hospital for evaluation of an elevated serum prostate specific antigen (PSA) level (191.10 ng/ml...
محفوظ في:
| الحاوية / القاعدة: | Anticancer Drugs |
|---|---|
| المؤلفون الرئيسيون: | , , , , , , , , , |
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
Lippincott Williams & Wilkins
2020
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7566291/ https://ncbi.nlm.nih.gov/pubmed/32804697 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CAD.0000000000000986 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|